Clinical Diagnostics Pax Neuroscience focuses on blood tests for depression diagnosis and antidepressant response, presenting a direct sales path to clinical laboratories, hospitals, and psychiatry departments seeking objective biomarkers to support treatment decisions.

Biomarker Opportunity Developing novel protein biomarkers from hypothesis-driven data sets with early clinical promise suggests opportunities to partner with biopharma and contract research organizations for companion diagnostics and assay development.

SBIR Validation Previous Small Business Innovation Research award indicates credibility with federal funding programs, which can be leveraged in grant-supported collaborations and to establish government-facing sales pitches.

Market Growth Depression is highlighted as a leading global disability concern, creating a favorable market tailwind for diagnostic tools and pharmacologic response tests that can differentiate Pax from broader biodev and analytics competitors.

Partnership Footprint With a lean team and revenue in the lower-mid range, there is a clear path to channel partnerships with larger pharma and medical device/instrument vendors to scale distribution, validation studies, and regulatory-ready offerings.